Clinical Application Progress of Stereotactic Radiotherapy for Hepatocellular Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 ZHANGJiang-zhou ,  LONGZhi-xiong

Second Department of Oncology, 5^th Hospital of Wuhan City, Wuhan 430050, Hubei Province, China;

Corresponding author：

LONGZhi-xiong, Email: longzhixiong@hotmail.com

Keywords：

Radiotherapy; Primary hepatic carcinoma; Stereotactic body radiation therapy; Clinical efficacy

DOI：

10.7507/1007-9424.20160033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize clinical application progress of stereotactic radiotherapy for primary hepatocellular carcinoma. Methods The literatures about the research progress of the stereotactic radiotherapy for primary hepatocellular carcinoma were reviewed. Results Radiotherapy for hepatocellular carcinoma is importantly based on the radiation biology of the liver and the radiophysics of the liver cancer. Stereotactic precision radiotherapy is an effective and low toxic treatment for early hepatocellular carcinoma, moreover, it alone or in combination with microwave ablation, hepatic artery chemoembolization for unresectable hepatocellular carcinoma is safe and effective method for the treatment. Conclusions The optimal dose model for hepatocellular carcinoma, hepatocellular carcinoma radical dose level are problems that need further exploration, and radiobiology, radiation physics research must be strengthened to explore it, stereotactic precision radiotherapy treatment modalities in the treatment of hepatocellular carcinoma position will become increasingly people attention.

Citation： ZHANGJiang-zhou, LONGZhi-xiong. Clinical Application Progress of Stereotactic Radiotherapy for Hepatocellular Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(1): 119-122. doi: 10.7507/1007-9424.20160033 Copy

1.	Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1):11-30.
2.	Ursino S, Greco C, Cartei F, et al. Radiotherapy and hepatocellular carcinoma:update and review of the literature. Eur Rev Med Pharmacol Sci, 2012, 16(11):1599-1604.
3.	Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy:review of evidence and future opportunities. Int J Radiat Oncol Biol Phys, 2013, 87(1):22-32.
4.	Dufour JF, Bargellini I, De Maria N, et al. Intemediate hepatocellular carcinoma:current treatments and future perspectives. Ann Oncol, 2013, 24 Suppl 2:ii24-ii29.
5.	Tang QH, Li AJ, Yang GM, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus:a comparative study. World J Surg, 2013, 37(6):1362-1370.
6.	Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 2007, 67 (1):225-231.
7.	Shimizu S, Shirato H, Xo B, et al.Three dimensional movement of a liver tumor detected by high speed magnetic resonance imaging. Radiother Oncol, 1999, 50(3):367-370.
8.	Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors:a single institution phaseⅠ-Ⅱstudy. Acta Oncol, 2006, 45(7):831-837.
9.	Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer, 2012, 118(12):3191-3198.
10.	Aitken KL, Hawkins MA. The role of radiotherapy and chemoradia-tion in the management of primary liver tumours. Clin Oncol (R Coll Radiol), 2014, 26(9):569-580.
11.	Sanuki N, Takeda A, Mizuno T, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol, 2013, 201(6):W812-W820.
12.	Takeda A, Sanuki N, Eriguchi T, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol, 2014, 29(2):372-379.
13.	Takeda A, Oku Y, Sanuki N, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol, 2012, 104(3):374-378.
14.	Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol, 2013, 28(3):530-536.
15.	Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma:A retrospective outcome analysis in 185 patients. Acta Oncol, 2014, 53(3):399-404.
16.	Olsen CC, Welsh J, Kavanagh BD, et al. Microscopic and macros-copic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys, 2009, 73(5):1414-1424.
17.	Eriguchi T, Takeda A, Sanuki N, et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys, 2013, 85(4):1006-1011.
18.	Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis:evaluation of radiological and pathological response. J Surg Oncol, 2012, 105(7):692-698.
19.	Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol, 2012, 7:166.
20.	Xi M, Zhang L, Zhao L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosisl. PLoS One, 2013, 8(5):e63864.
21.	张江洲, 龙志雄.微波消融联合立体定向放疗治疗原发及复发性肝癌的临床研究.肿瘤防治研究, 2014, 41(6):649-652.
22.	叶云飞, 杨倞, 孙永健, 等.巨块型肝癌的放射治疗临床效果探讨(附190例报告).现代生物医学进展, 2013, 13(25):4947-4949.
23.	肖绍文, 张珊文.肿瘤放射治疗临床进展.科技导报, 2014, 32(26):37-41.
24.	颜桂明, 陈国付, 张飞燕.肿瘤精确放疗技术进展.医学理论与实践, 2015, 28(2):164-166.
25.	Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intemediater-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembolization. Cancer treat Rev, 2011, 37(3):212-220.
26.	Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer, 2012, 118(21):5424-5431.
27.	李坤, 李桂杰, 张建东, 等.肝动脉化疗栓塞联合三维适形放射治疗原发性肝癌的临床疗效.中华消化病与影像杂志:电子版, 2013, 3(2):73-75.
28.	Tanaka Y, Nakazawa T, Komori S, et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels:efficacy and outcomes. J Gastroenterol Hepatol, 2014, 29(2):352-357.
29.	Ibarra RA, Rojas D, Snyder L, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for nonresectable primary liver tumors. Acta Oncol, 2012, 51(5):575-583.
30.	Zhong NB, LV GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas:A clinical study. Molecular and Clinical Oncology, 2013, 2(5):839-844.
31.	Wu DH, Chen LH. Efficacy of 3-dimensional conformal hypofractionated single high-dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma. Chin J Cancer, 2004, 23(7):825-828.
32.	Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver, 2012, 6(2):139-148.
33.	Xi M, Liu MZ, Zhang L, et al. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol, 2009, 92(2):255-259.
34.	Bae SH, Kim MS, Cho CK, et al. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci, 2013, 28(2):213-219.
35.	Naoko Sanuki, Atsuya Takeda, Etsuo Kunieda. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol, 2014, 20(12):3100-3111.
36.	Que JY, Lin LC, Lin KL, et al. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol, 2014, 9:120.
37.	Wu TH, Yu MC, Chen TC, et al. Encapsulation is a significant prog-nostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol, 2012, 105(1):85-90.

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin, 2013, 63(1):11-30.
2. Ursino S, Greco C, Cartei F, et al. Radiotherapy and hepatocellular carcinoma:update and review of the literature. Eur Rev Med Pharmacol Sci, 2012, 16(11):1599-1604.
3. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy:review of evidence and future opportunities. Int J Radiat Oncol Biol Phys, 2013, 87(1):22-32.
4. Dufour JF, Bargellini I, De Maria N, et al. Intemediate hepatocellular carcinoma:current treatments and future perspectives. Ann Oncol, 2013, 24 Suppl 2:ii24-ii29.
5. Tang QH, Li AJ, Yang GM, et al. Surgical resection versus conformal radiotherapy combined with TACE for resectable hepatocellular carcinoma with portal vein tumor thrombus:a comparative study. World J Surg, 2013, 37(6):1362-1370.
6. Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys, 2007, 67 (1):225-231.
7. Shimizu S, Shirato H, Xo B, et al.Three dimensional movement of a liver tumor detected by high speed magnetic resonance imaging. Radiother Oncol, 1999, 50(3):367-370.
8. Méndez Romero A, Wunderink W, Hussain SM, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors:a single institution phaseⅠ-Ⅱstudy. Acta Oncol, 2006, 45(7):831-837.
9. Price TR, Perkins SM, Sandrasegaran K, et al. Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma. Cancer, 2012, 118(12):3191-3198.
10. Aitken KL, Hawkins MA. The role of radiotherapy and chemoradia-tion in the management of primary liver tumours. Clin Oncol (R Coll Radiol), 2014, 26(9):569-580.
11. Sanuki N, Takeda A, Mizuno T, et al. Tumor response on CT following hypofractionated stereotactic ablative body radiotherapy for small hypervascular hepatocellular carcinoma with cirrhosis. AJR Am J Roentgenol, 2013, 201(6):W812-W820.
12. Takeda A, Sanuki N, Eriguchi T, et al. Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. J Gastroenterol Hepatol, 2014, 29(2):372-379.
13. Takeda A, Oku Y, Sanuki N, et al. Dose volume histogram analysis of focal liver reaction in follow-up multiphasic CT following stereotactic body radiotherapy for small hepatocellular carcinoma. Radiother Oncol, 2012, 104(3):374-378.
14. Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol, 2013, 28(3):530-536.
15. Sanuki N, Takeda A, Oku Y, et al. Stereotactic body radiotherapy for small hepatocellular carcinoma:A retrospective outcome analysis in 185 patients. Acta Oncol, 2014, 53(3):399-404.
16. Olsen CC, Welsh J, Kavanagh BD, et al. Microscopic and macros-copic tumor and parenchymal effects of liver stereotactic body radiotherapy. Int J Radiat Oncol Biol Phys, 2009, 73(5):1414-1424.
17. Eriguchi T, Takeda A, Sanuki N, et al. Acceptable toxicity after stereotactic body radiation therapy for liver tumors adjacent to the central biliary system. Int J Radiat Oncol Biol Phys, 2013, 85(4):1006-1011.
18. Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepatocellular carcinoma and cirrhosis:evaluation of radiological and pathological response. J Surg Oncol, 2012, 105(7):692-698.
19. Dewas S, Bibault JE, Mirabel X, et al. Prognostic factors affecting local control of hepatic tumors treated by Stereotactic Body Radiation Therapy. Radiat Oncol, 2012, 7:166.
20. Xi M, Zhang L, Zhao L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosisl. PLoS One, 2013, 8(5):e63864.
21. 张江洲, 龙志雄.微波消融联合立体定向放疗治疗原发及复发性肝癌的临床研究.肿瘤防治研究, 2014, 41(6):649-652.
22. 叶云飞, 杨倞, 孙永健, 等.巨块型肝癌的放射治疗临床效果探讨(附190例报告).现代生物医学进展, 2013, 13(25):4947-4949.
23. 肖绍文, 张珊文.肿瘤放射治疗临床进展.科技导报, 2014, 32(26):37-41.
24. 颜桂明, 陈国付, 张飞燕.肿瘤精确放疗技术进展.医学理论与实践, 2015, 28(2):164-166.
25. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intemediater-stage hepatocellular carcinoma:available evidence and expert opinion on the use of transarterial chemoembolization. Cancer treat Rev, 2011, 37(3):212-220.
26. Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer, 2012, 118(21):5424-5431.
27. 李坤, 李桂杰, 张建东, 等.肝动脉化疗栓塞联合三维适形放射治疗原发性肝癌的临床疗效.中华消化病与影像杂志:电子版, 2013, 3(2):73-75.
28. Tanaka Y, Nakazawa T, Komori S, et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels:efficacy and outcomes. J Gastroenterol Hepatol, 2014, 29(2):352-357.
29. Ibarra RA, Rojas D, Snyder L, et al. Multicenter results of stereotactic body radiotherapy (SBRT) for nonresectable primary liver tumors. Acta Oncol, 2012, 51(5):575-583.
30. Zhong NB, LV GM, Chen ZH. Stereotactic body radiotherapy combined with transarterial chemoembolization for huge (≥10 cm) hepatocellular carcinomas:A clinical study. Molecular and Clinical Oncology, 2013, 2(5):839-844.
31. Wu DH, Chen LH. Efficacy of 3-dimensional conformal hypofractionated single high-dose radiotherapy combined with transcatheter arterial chemoembolization for portal vein tumor thrombus in patients with hepatocellular carcinoma. Chin J Cancer, 2004, 23(7):825-828.
32. Lee IJ, Seong J. The optimal selection of radiotherapy treatment for hepatocellular carcinoma. Gut Liver, 2012, 6(2):139-148.
33. Xi M, Liu MZ, Zhang L, et al. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol, 2009, 92(2):255-259.
34. Bae SH, Kim MS, Cho CK, et al. Feasibility and efficacy of stereotactic ablative radiotherapy for Barcelona Clinic Liver Cancer-C stage hepatocellular carcinoma. J Korean Med Sci, 2013, 28(2):213-219.
35. Naoko Sanuki, Atsuya Takeda, Etsuo Kunieda. Role of stereotactic body radiation therapy for hepatocellular carcinoma. World J Gastroenterol, 2014, 20(12):3100-3111.
36. Que JY, Lin LC, Lin KL, et al. The efficacy of stereotactic body radiation therapy on huge hepatocellular carcinoma unsuitable for other local modalities. Radiat Oncol, 2014, 9:120.
37. Wu TH, Yu MC, Chen TC, et al. Encapsulation is a significant prog-nostic factor for better outcome in large hepatocellular carcinoma. J Surg Oncol, 2012, 105(1):85-90.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Application Progress of Stereotactic Radiotherapy for Hepatocellular Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content